Saturday, 3 October 2026European Markets

Euro Surges 14% Against Dollar in 2025 as US Currency Hits Three-Year Low

The euro gained 14% versus the dollar in 2025 as the Bloomberg Dollar Spot Index fell to its lowest level since 2022. The British pound rose 7% against the dollar over the same period, while safe-haven flows pushed the Swiss franc higher amid currency market volatility.

Euro Surges 14% Against Dollar in 2025 as US Currency Hits Three-Year Low
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The euro has surged 14% against the US dollar in 2025, marking a significant shift in currency markets as the Bloomberg Dollar Spot Index dropped to its lowest level since 2022. The dollar's decline has triggered a multi-year currency realignment affecting European-American trade dynamics.

The British pound gained 7% versus the dollar over the same period, though recent pressure pushed the GBP/EUR rate to €1.13—its weakest since April 2023. Currency analysts forecast further pound weakness, with Jordan Rochester at Mizuho Bank projecting a potential decline below $1.30.

Simon Phillips, Managing Director at No1 Currency, noted mounting pressure on sterling as European currencies strengthen relative to both the dollar and pound. The Swiss franc has attracted safe-haven flows as investors seek stability during the currency market upheaval.

The euro's strength complicates EU-US trade relations at a time when European exporters face competitiveness challenges. A stronger euro makes European goods more expensive for American buyers, potentially widening the trade imbalance between the two economic blocs.

Currency strategists attribute the dollar's weakness to multiple factors affecting US monetary policy and fiscal stability. The realignment has pushed the Bloomberg Dollar Spot Index down materially against major currencies, with analysts tracking the trend.

European Central Bank policymakers now face decisions on whether the euro's appreciation warrants intervention or policy adjustments. The 14% gain against the dollar represents one of the euro's strongest performances in recent years, raising questions about export competitiveness across eurozone economies.

UK gilt markets have shown volatility alongside currency movements, with 30-year yields climbing to 5.21%—the highest since August's 1998-era levels. The pound's dual pressure against both the euro and dollar reflects investor uncertainty about UK fiscal policy and economic outlook.

Market participants are monitoring whether the dollar's weakness marks a sustained trend or temporary adjustment. The currency realignment carries implications for European corporate earnings, cross-border investment flows, and central bank policy coordination between the Federal Reserve and European monetary authorities.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com